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Abstract
Background: For patients with locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is
recommended as standard therapy. So far, no predictive or prognostic molecular factors for patients undergoing
multimodal treatment are established. Increased angiogenesis and altered tumour metabolism as adaption to
hypoxic conditions in cancers play an important role in tumour progression and metastasis. Enhanced expression
of Vascular-endothelial-growth-factor-receptor (VEGF-R) and Transketolase-like-1 (TKTL1) are related to hypoxic
conditions in tumours. In search for potential prognostic molecular markers we investigated the expression of
VEGFR-1, VEGFR-2 and TKTL1 in patients with LARC treated with neoadjuvant chemoradiotherapy and cetuximab.
Methods: Tumour and corresponding normal tissue from pre-therapeutic biopsies of 33 patients (m: 23, f: 10;
median age: 61 years) with LARC treated in phase-I and II trials with neoadjuvant chemoradiotherapy (cetuximab,
irinotecan, capecitabine in combination with radiotherapy) were analysed by quantitative PCR.
Results: Significantly higher expression of VEGFR-1/2 was found in tumour tissue in pre-treatment biopsies as well
as in resected specimen after neoadjuvant chemoradiotherapy compared to corresponding normal tissue. High
TKTL1 expression significantly correlated with disease free survival. None of the markers had influence on early
response parameters such as tumour regression grading. There was no correlation of gene expression between the
investigated markers.
Conclusion: High TKTL-1 expression correlates with poor prognosis in terms of 3 year disease-free survival in
patients with LARC treated with intensified neoadjuvant chemoradiotherapy and may therefore serve as a
molecular prognostic marker which should be further evaluated in randomised clinical trials.
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Background
Neoadjuvant chemoradiotherapy has become standard
treatment for locally advanced rectal cancer due to
improved local tumour control. Distant metastases are
currently the predominant cause for treatment failure
[1]. Therefore, the search for prognostic and predictive
markers has been widely promoted in the last few years
[2,3]. To date, no validated prognostic or predictive
molecular marker in the setting of locally advanced rec-
tal cancer has been established.
Angiogenesis as a central process in progression of
solid tumours is a well-established aspect of cancer biol-
ogy [4]. Inhibition of involved tyrosine kinase receptors
such as the epidermal growth factor (EGFR) and the
vascular endothelial growth factor receptor (VEGFR) or
its ligand VEGF is effective in several tumour types
[5,6]. VEGFR-2 is believed to be the major mediator of
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said to play its primary role during embryogenesis and
regulates apoptosis and tumour growth in malignancies
[7]. Several studies have outlined a trend towards more
aggressive tumour growth in terms of distant metastasis
in patients with VEGF-overexpressing rectal cancer
undergoing neoadjuvant treatment [8]. However, expres-
sion data of the different VEGF subtypes and their
receptors in colorectal cancer still remain controversial
[9-11] and their prognostic impact on patients treated
with neoadjuvant cetuximab-based chemoradiotherapy
has not yet been evaluated.
Many cancers show a strongly enhanced glycolytic
metabolism of carbohydrates even in the presence of
oxygen ("aerobic glycolysis”), a phenomenon firstly
described by Nobel laureate Otto Warburg ("Warburg
effect”) [12]. The detection of the Transketolase-like-1
(TKTL1) protein and its role in the pentose phosphate
pathway (PPP) first described a link between enhanced
glycolysis and cancer [13]. Increased TKTL1 expression
on mRNA and protein level correlates with poor patient
outcome and metastasis in many solid tumours [14-18].
Specific inhibition of TKTL1 mRNA has been shown to
inhibit cancer cell proliferation in functional studies
[14,17].
In the present study, we aimed to analyze the poten-
tial prognostic and predictive influence of VEGFR-1/2
and TKTL1 expression on early response parameters
such as pathological tumour regression grading (TRG)
and tumour downstaging and on 3-year disease-free sur-
vival in patients with LARC undergoing cetuximab-
based chemoradiotherapy within clinical trials.
Methods
Patients and Treatment
The present analysis comprises patients with histologi-
cally confirmed, locally advanced non-metastatic rectal
adenocarcinoma (endorectal ultrasound stage cT3-4, any
N or cT2, N+ distal rectum). All patients participated in
clinical trials of intensified neoadjuvant chemoradiother-
apy including weekly irinotecan (40 - 50 mg/m
2)a n d
cetuximab (initial dose of 400 mg/m
2 then 250 mg/m
2),
and daily capecitabine (400 - 500 mg/m
2 b.i.d.) in com-
bination with pelvic radiotherapy (45 Gy + 5.4 Gy) as
previously described [19,20]. Follow up of patients was
carried out according to the German study group for
gastrointestinal Oncology [21]. Patient characteristics
are listed in Table 1.
Patients provided written informed consent for the
participation in the clinical study as well as for the inves-
tigation of biopsy material. The clinical study protocol
was reviewed and approved by the local institutional
review board and the study was performed according to
the Declaration of Helsinki.
Pathological assessment and definition of tumour
response
Surgery was performed 4 - 6 weeks after the completion
of chemoradiotherapy. The pathological routine work-
up was described earlier [22].
Two classification systems were applied to describe
response to chemoradiotherapy. The grade of histopatho-
logical regression has first been described using the Japa-
nese Society for Cancer of the Colon and Rectum
(JSCCR) grading system [23]. Tumours were classified as
good-responders when assigned to tumour regression
grades 2 or 3 (TRG 2 or TRG 3), and as bad-responders
at regression grades 0 or 1 (TRG 0 or TRG 1).
Moreover, the histopathological downstaging after
completion of preoperative chemoradiotherapy was used
as surrogate parameter of tumour response, as
previously described by Valentini et al [24]. A T-level
Table 1 Patient and tumour characteristics in 33 patients
treated with cetuximab based chemoradiotherapy
Patients (n) %
Patients included 33 100
Median age (range) 61 (33 - 76)
Gender
Male 23 70
Female 10 30
Performance Status (ECOG*)
0 23 70
1 92 7
2 13
Tumour marker
CEA, median (range) 2,4 μg/l (0.5 - 50,3)
CA 19-9, median (range) 10 kU/l (1 - 298)
Clinical T-staging (TRUS
§§)
cT2 61 8
cT3 24 73
cT4 39
Clinical N-staging (TRUS
§§)
cN negative 10 30,3
cN positive 23 69,7
TRG
§ (JSCCR
┼┼)
0 13
1a 61 8
1b 41 2
2 19 58
3 39
§§: Transrectal ultrasound; §: Tumour regression grade;
┼┼ = Japanese Society
for Cancer of the Colon and Rectum.
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a sign of response.
Tissue samples, Real-time quantitative polymerase chain
reaction
Tumour material was obtained during rectoscopy before
the initiation of chemoradiotherapy and during surgery
of the primary tumour. Tumour biopsies (n = 33) and
matching healthy mucosa (n = 33) were stored in RNA-
later (Quiagen, Hilden, Germany) in liquid nitrogen, and
stored at -80°C until further extraction. RNA extraction
and cDNA synthesis was performed according to stan-
dard protocols [25]. Total RNA was extracted after
homogenisation of 15-30 mg tissue with the Ultra Tur-
rax Tube Drive (Ika, Staufen, Germany) using TRIzol™
reagent (Invitrogen, Karlsruhe, Germany) according to
the manufacturer’s instructions. RNA was reversely tran-
scribed using random hexamer priming and MMLV
reverse transcriptase (Invitrogen).
Expression analysis of VEGFR-1, VEGFR-2 and TKTL1
was performed using the LightCycler instrument 1.5
(Roche Diagnostics, Mannheim, Germany). For
sequences of amplification primers and hybridisation
probes used see additional file 1. Each 20 μl reaction
mix contained 4 μl LightCycler Faststart DNA Master-
plus Hyb Probes Master Mix (Roche Diagnostics), 2 μl
cDNA template or plasmid dilution, 0.5 μM forward pri-
mer and 0.5 μM reverse primer, 0.25 μM anchor probe
and 0.25 μM sensor probe (TIB Molbiol, Berlin, Ger-
many). Cycler conditions were the following: 10 min
denaturation at 95°C, 50 cycles of 10 sec at 60°C
(annealing VEGFR-1, -2, and TKTL1) and 26 sec at 72°C
(elongation). A 5 log series of plasmid dilutions was
amplified within the PCR runs for quantification of
VEGFR-1, -2 and TKTL1. The LightCycler software pre-
pares standard curves using linear regression analysis of
the plasmid dilutions and calculates copy numbers of
the unknown sample [26]. Values below the lowest stan-
dard dilution for TKTL1 (4 copies) and VEFGR-1/2 (40
copies) were assigned as negative. Beta-Glucuronidase
(GUS) mRNA was quantified as internal control as pre-
viously described [27].
Cloning of Quantification standards
Cloning and transformation of the PCR products of
TKTL1, VEGFR-1 and VEGFR-2 amplified from cell
lines (SW480, K562 obtained from DSMZ, Braunsch-
weig, Germany) was performed according to the manu-
facturer’s instructions using the PCR2.1 TOPO vector
(Invitrogen). Amplification reactions were undertaken
for 32 cycles at 60°C annealing temperature. Cloning
and transformation into Escherichia coli TOPO10F’ was
performed according to the manufacturer’s instructions
(Invitrogen). Plasmid DNA containing the desired
construct was isolated using the Plasmid Mini Kit
(Qiagen). Insertion sequences were confirmed by direct
sequencing. The resulting plasmid was linearized by
Not1 digestion (Roche Diagnostics). Dilutions of the lin-
earized plasmid were prepared in 10 mM Tris-HCl (pH
8.0) and 1 mM ethylenediaminetetraacetic acid contain-
ing 20 mg/mL tRNA (Roche Diagnostics).
ß-Glucuronidase (GUS) mRNA transcripts were
measured as an internal control using a standard plas-
mid (pME-2) containing BCR-ABL, ABL,a n dGUS
sequences [27]
In order to minimize dilution error of different plas-
mids containing target and housekeeping gene a com-
mon plasmid containing TKTL1 and GUS was
constructed for further use using a previously published
method [27].
KRAS, PTEN and Survivin analysis
KRAS mutation analysis was performed for all samples
by direct sequencing from DNA of microdissected
tumor tissue samples as described [28]. PTEN status
was determined by immunohistochemistry (IHC) using
the PTEN antibody as described [28] (1:400, Cascade
Bioscience, Winchester, MA, USA). All 33 patients were
screened for PTEN mutations, 30 of which were evalu-
able. Three samples could not be taken into the analysis
due to poor sample quality. Survivin expression analysis
was performed on cDNA level of 30 patients from the
studygroup using qPCR.
Statistical analysis
Differences in expression levels were compared using
two-tailed Mann Whitney test. Differences in regression
rates concerning the investigated tissue markers were
evaluated by means of a two sided Fisher’sE x a c tt e s t .
Disease-free survival was defined as the time between
the start of chemoradiotherapy and tumour relapse
(local failure and/or distant metastases) or death due to
non-tumour related causesu s i n gt h eK a p l a n - M e i e r
method. Cut off level of median gene expression was
used to divide low and high expressing groups. A p-
value of less than 0.05 was considered statistically
significant.
Results
Patients, tumour characteristics and expression levels in
tumour tissue
Patient and tumour characteristics are depicted in Table
1. Tumour tissue of a total of 33 patients (n = 23 male,
n = 10 female, median age 61, range 33 - 76) was ana-
lysed. TKTL1 expression was determined in 33 patients,
while VEGRFR-2 expression was analysed in 32 and
VEGFR-1 expression in 26 patients only due to scant-
ness of tumour tissue.
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Page 3 of 9Normalised VEGFR-1/-2 expression of patients with
LARC was significantly higher in pre-treatment tumour
tissue in comparison to the corresponding normal
mucosa (VEGFR-1; p = 0.0023 and VEGFR-2; p=
0.0005) but failed to be statistically significant for
TKTL1 (p = 0.082). Accordingly, after completion of
chemoradiotherapy higher VEGFR-1/-2 expression levels
( p=0 . 0 2 5 ;p=0 . 0 6 3 )w e r eo b s e r v e di nt u m o u rt i s s u e
as compared to healthy mucosa at time of surgery,
whereas no differences in gene expression levels of
VEGFR-1 and -2 were observed in tumour samples
before and after neoadjuvant radiotherapy (Figure 1).
Expression levels and pathological tumour response
(TRG, pCR)
A total of 11 out of 33 patients showed a poor response
(33%; defined as TRG of 0 or 1), while 22 patients had
good response (67%; TRG 2 or 3, Table 1). Pathological
T-downstaging was accomplished in 15 patients (45%,
“T-responder”), 3 of whom (9%) achieved a pathological
complete remission (ypT0 N0). No significant correla-
tion between the two scores could be seen in our cohort
(CI: 0,7-2,1, p-value:0,4).
Median pre-treatment expression levels of the three
genes were used as a cut off value, dividing patients into
low and high-expression groups (Figure 1) No signifi-
cant correlation was observed neither for the JSCCR
grading (TRG) nor the complete pathological response
(pCR) nor for gene expression levels (Table 2).
Gene Expression levels and DFS
All but one patient underwent curative surgery. The lat-
ter had an irresectable T4-tumour and revealed tumour
progression with peritoneal spread during chemora-
diotherapy. Median follow-up time was 33 months
(range: 9-51). Local recurrence and distant metastases
were recorded in two (12.5%) and 10 patients (65%),
respectively.
A longer three-year DFS could be observed in patients
with low TKTL1 expression (3-year DFS: 87% versus
39%, n = 33, p = 0.01, HR: 0.19, CI: 0,05-0,6), while
three-year DFS was virtually identical for patients with
high vs. low VEGFR-1 expression (3-year DFS: 69% ver-
sus 68%, n = 26, p = 0,9, HR: 1,04, CI: 0,26-4,2). The
impact of VEGFR-2 expression on DFS failed statistical
significance but a trend was observed regarding 3-year
DFS in favour of patients with lower VEGFR-2 expres-
sion (3-year DFS: 81% versus 53%, n = 32, p = 0.19,
HR:0,43, CI: 0,13-2,15; see Figure 2).
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Figure 1 Comparison of normalised median expression levels
of VEGFR-1, VEGFR-2 and TKTL1 in tumour and healthy mucosa.
Comparison of normalised median expression levels of VEGFR-1
(VEGFR-1/GUS), VEGFR-2 (VEGFR-2/GUS) and TKTL1 (TKTL1/GUS) in
tumour and healthy mucosa before (A1, B1) and after neoadjuvant
treatment (A2; B2) (Box and whiskers plot, 10-90
th percentile). A1:
normal mucosa before neoadjuvant chemoradiotherapy; A2: normal
mucosa after neoadjuvant chemoradiotherapy; B1 tumour tissue
before neoadjuvant chemoradiotherapy; B2: tumour tissue after
neoadjuvant chemoradiotherapy;
Table 2 Prognostic value of pathological tumour
response for VEGFR-1, VEGFR-2, and TKTL1
VEGFR-1/GUS ≤
Median (n = 13)
VEGFR-1/GUS >
Median (n = 13)
p-value
TRG
┼ 2 - 3 9 (69.2%) 8 (61.5%) p = 1.0
pCR* (ypT0 N0) 2 (15.4%) 1 (7.7%) p = 1.0
VEGFR-2/GUS ≤
Median (n = 16)
VEGFR-2/GUS >
Median (n = 16)
TRG
┼ 2 - 3 12 (75%) 9 (56%) p = 0.19
PCR* (ypT0 N0) 2 (16.7%) 1 (6.3%) p = 1.0
TKTL1/GUS ≤
Median (n = 17)
TKTL1/GUS >
Median (n = 16)
TRG┼ 2 - 3 11 (64.5%) 11 (68.8%) p = 1.0
PCR* (ypT0 N0) 1 (5.9%) 2 (12.5%) p = 0.6
pathological complete remission,
┼Tumour regression grading.
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Page 4 of 9Correlation of TKTL1 expression with clinical and
molecular findings
The high and low expressing patient groups are com-
pared in Table 3 with respect to several clinical and
molecular parameters. Median age in patients with a
higher TKTL1 expression was younger compared to
patients with low TKTL1 expression. No significant dif-
ferences could be seen in initial tumour stage and TRG.
Serum tumour markers in the patient group with higher
TKTL1 expression were slightly higher, but this did not
reach statistical significance (p-value for CEA p = 0.07,
n = 16, p-value for CA 19.9, p = 0.18, n = 16). Patients
with high TKTL1 levels eventually developed metastases
or local recurrence significantly more often than
patients with low TKTL1 levels (11 vs. 1 pts., p =
0.0002). TKTL1 expression was correlated to VEGFR-1/
2 and to PTEN, KRAS and Survivin expression in our
cohort. Expression of the latter molecular markers has
previously been published by our group [28,29]. No cor-
relation between high TKTL1 expression and VEGFR-1
or -2 expression was demonstrated, while a tendency
towards higher survivin expression in the TKTL1
overexpressing group could be detected (13 vs 17 pts.,
p = 0.08).
Discussion
Despite intensive neoadjuvant treatment regimens using
chemotherapy and radiotherapy, 35-40% of patients with
locally advanced rectal cancer (LARC) eventually will
develop distant metastases and die of this disease. To
date, no validated prognostic or predictive molecular
marker in the setting of locally advanced rectal cancer is
established to tailor treatment individually to the
patients.
Angiogenesis is a central process in tumour progres-
sion, and enhanced glycolytic metabolism of carbohy-
drates even in the presence of oxygen ("aerobic
glycolysis”) has been demonstrated to be involved in
progression and resistance in several solid tumours
[3,4,30,31]. In the present study, we evaluated the poten-
tial prognostic and predictive impact of VEGFR-1,
VEGFR-2 and TKTL1 mRNA expression levels in
patients with LARC receiving intensified neoadjuvant
chemoradiotherapy with capecitabine, irinotecan and
cetuximab. Quantification of the examined genes was
performed using qPCR and normalized against the
housekeeping gene GUS.
The main finding of this study was an inferior 3-year
DFS for patients with high TKTL1 expression as com-
pared to those with low TKTL1 expression using qPCR
(3 year DFS: 39% vs 87%; p = 0.017). TKTL1,a na l t e r e d
isoform of the transketolase gene, is upregulated in
many human cancers [14-17,32]. TKTL1 protein renders
tumour cells autonomous by means of infinite glucose
consumption irrespective of oxygen supply [13,16].
Transketolase reactions in the pentose phosphate path-
way (PPP) convert glucose to ribose for nucleic acid
synthesis and generate NADPH, a reducing agent
required for synthesis reactions in growing tumour cells.
More than 85% of the nucleic acid in certain tumours
derives from ribose generated in the nonoxidative part
of the PPP [33].
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Figure 2 Probability of disease-free survival correlated to gene
expression levels of TKTL1, VEGFR-1 and VEGFR-2;. Probability of
disease-free survival correlated to gene expression levels of TKTL1,
VEGFR-1 and VEGFR-2; Median pre-treatment expression level was
defined as cut-off level for the respective gene expression in the
investigated rectal cancer patients.
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Page 5 of 9Shin and co-workers described an upregulation of gly-
colytic enzymes including Transketolase in 5-FU resis-
tant colon cancer cell lines [34], an argument for the
potential involvement of TKTL1 in progression and
therapy resistance.
TKTL1 expression in colon cancer was shown to be
upregulated as compared to TKT and TKTL2 expression
using immunohistochemistry and cell culture assays
[14,17]. Significant reduction in cell growth and viability
in human LoVo and HCT116 colon cancer cells treated
with TKTL1 siRNA as compared to LoVo/HCT116 cells
without RNAi treatment in a cell culture model using
quantitative PCR was demonstrated by two different
groups [14,17]. Langbein et al. [16] examined untreated
tumour tissue of 70 colon cancer patients and showed
overexpression of TKTL1 in invasive carcinomas as
compared to healthy tissue and non-invasive tumours
on protein level. Overexpression of the TKTL1 protein
was related to lower disease specific survival. In the
same study, five colon cancer samples have been ana-
lysed by quantitative PCR, also showing TKTL1 overex-
pression in invasive carcinomas on mRNA level.
Although TKTL1 expression has been analysed in many
solid tumours, to date no such analysis has been done for
rectal cancer. Most of the studies focusing on TKTL1
expression in solid malignancies examined TKTL1 expres-
sion levels via immunohistochemistry, whereas expression
on cDNA level has been examined less frequently.
Altered glucose consumption may also have therapeu-
tic consequences: It became apparent that depletion of
ATP by glycolytic inhibition potently induced apoptosis
in multidrug-resistant cells in vitro [33,35]. Inhibition of
the ultimate step in glycolysis (the conversion of pyru-
vate to lactate) has been proven to be effective in vivo
and in vitro in breast cancer [36]. In addition, the acti-
vation of transketolases by application of thiamine sti-
mulates tumour growth [37]. Specific inhibition of
TKTL1 might be a useful target in this setting in cases,
where TKTL1 expression is upregulated. To date, many
preclinical glucose inhibitors have been developed, giv-
i n gr i s et oap o s s i b l yn e ws u b s t a n c eg r o u pi nt h en e a r
future [38].
In our analysis, TKTL1 expression significantly corre-
lates with DFS and development of metastasis, whereas
no significant difference for median survival, local recur-
rence rates or death could be found. The reason for this
controversary again might be found in the sample size:
all investigations show a trend towards better outcome
in low TKTL1 expressing patients and should therefore
be analyzed again in a larger cohort.
No correlation of TKTL1 expression with the other
investigated markers could be detected in our study.
Lack of prognostic value for survivin expression and
KRAS/PTEN mutation status is in line with prior find-
ings of our group [28,29]. A slight tendency towards
higher survivin expression in patients overexpressing
Table 3 Clinical and laboratory findings dependent on TKTL1 expression status
TKTL1/GUS ≤
Median (n = 17)
TKTL1/GUS >
Median (n = 16)
P value
Median age (n = 33): 61 years 63 59 p = 0.89
Clinical tumour stage uN negative n = 5 (29%) uN negative n = 5 (31%) p = 1.0
uN positive n = 12 (71%) uN positive n = 11 (69%)
Pathological tumour stage (n = 32) ypT0N0 n = 1 ypT0N0 n = 2 p = 0.69
ypT1-2N0 n = 6 ypT1-2N0 n = 6
ypT3-4N0 n = 6 ypT3-4N0 n = 2
ypTanyN+ n = 4 ypTanyN+ n = 5
CEA (median) 2.1 4.25 p = 0.074
CA 19-9 10 23 p = 0.18
VEGFR1 (median) 0.4125; n = 10 0.1034; n = 16 p = 0.19
VEGFR2 (median) 0.4413; n = 16 0.8241; n = 16 p = 0.11
Survivin (n = 30) (median) 6.4; n = 17 8.5; n = 13 p = 0.081
KRAS mutated (n = 14/33) n = 6 (35%) n = 8 (50%) p = 0.49
Loss of PTEN (n = 2/30) n = 1/16 (6%) n = 1/14 (7%) p = 1.0
Local recurrence n = 0 (0%) n = 2 (12.5%) p = 0.22
Metastasis during follow up n = 1 (6%) n = 9 (56%) p = 0.0024
Median DFS ∞ (months) 39 23 p = 0.017
Death n = 2 (12%) n = 4 (25%) p = 0.39
Median Survival (months) 39 26 p = 0.26
∞ disease-free survival
Schwaab et al. BMC Cancer 2011, 11:363
http://www.biomedcentral.com/1471-2407/11/363
Page 6 of 9TKTL1 can be regarded as a possible response of
tumour cells to hypoxic conditions. Survivin has been
shown to being secreted as anti-apoptotic protein under
hypoxic conditions [39].
In contrast to our findings concerning TKTL1,
VEGFR-1/-2 expression does not seem to play a role as
ap r e d i c t i v eo rp r o g n o s t i cm a r k e ri nL A R Ci no u r
cohort.
Importance of VEGF-a sw e l la sVEGF-subtype- and
receptor-overexpression in solid tumours has been
widely discussed in the last few years. VEGFR-1 is said
to mediate biologic activity in human cancer cells [7],
VEGFR-2 regulates downstream molecules such as PI3K
or AKT and therewith steers endothelial differentiation,
DNA synthesis and proliferation [40]. However, the
actual impact of the receptors on therapeutic outcome
and prognosis remains controversial. André et al. [9]
found increased expression of VEGFR-1 and one of its
ligands VEGF-A on mRNA level in colon cancers, but
could not outline a prognostic value. Bertolini and cow-
orkers found no significant association between baseline
expression of VEGF (measured by immunohistochemis-
try) and pCR, disease free survival or overall survival
analysing 91 patients with LARC. An increase in VEGF
expression after the neoadjuvant treatment could be
observed [41].
Another study analyzed VEGF expression using immu-
nohistochemistry in 81 patients with LARC receiving
neoadjuvant radiotherapy [5]. No significant correlation
of VEGF-expression with the pCR and local relapse rate
was observed while disease free survival was poor due to
an increased rate of distant metastases.
In contrast, Zlobec et al. [8] analyzed 104 patients and
found a significant correlation of VEGF levels with pCR
rates using immunohistochemistry. Both studies may be
criticized because pre-treatment was not standardized in
the investigated patient population and differences
between patients receiving radiotherapy only and those
undergoing chemoradiation cannot be ruled out.
Our findings underline the involvement of VEGFR-1/-
2 in primary tumour growth and progression of rectal
cancer due to significantly increased levels compared to
normal tissue which is in line with the results reported
by others [9]. VEGFR-1/-2 expression was not altered by
the chemoradiotherapy regimen applied to the present
patient group. VEGFR-1/2 expression did not correlate
with tumour regression grade or tumour downsizing.
Accordingly, no significant correlation between VEGFR-
1/-2 expression and DFS has been noted. However, a
trend can be seen towards a better prognosis for
patients with low VEGFR-2 expression (Figure 2).
VEGFR-2 expression should therefore be analyzed with
a larger number of patients. Several studies have ana-
lyzed gene expression by immunohistochemistry, while
the present analysis has focused on mRNA expression
of VEGF-receptors, which could explain the different
results.
The lack of correlation between TKTL1 and VEGFR-
1/2 expression (Table 3) suggests that many different
other mechanisms are involved in tumour growth and
metastasis and that a change in tumour metabolism is
only one of many alterations [42]. Again, it has to be
mentioned that the sample size of the cohort was rela-
tively low due to scantness of tumour tissue available,
and investigation of a larger cohort size should be done
in order to prove this hypothesis.
Conclusion
High TKTL1 expression strongly correlated with poor
outcome in patients with LARC receiving neoadjuvant
intensified chemoradiotherapy in the present analysis
and may therefore be regarded as a potential prognostic
marker. Further validation of TKTL1 in larger patient
cohorts using multivariate analysis appears to be war-
ranted. It also has to be proved, whether TKTL1 expres-
sion as a predictive marker can be used in patient
groups with other treatment regimens apart from 5FU/
cetuximab/radiotherapy. Moreover, glucose metabolism
as a “druggable” target in solid tumours is under current
investigation and the potential links between high
TKTL1 expression and the metastatic potential of
tumours deserves further research. Expression of
VEGFR-1/-2 did not correlate with disease-free survival
in our study.
Additional material
Additional file 1: Primer sequences of VEGFR-1/-2 and TKTL1. Primer
sequences of VEGFR-1/-2 and TKTL1 used in described PCR assays.
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